Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Tan JCO PRecis Oncol 2022 epigenetics germline
2022
Beckman Coulter Life Sciences and Pillar Biosciences Sign Application Development Agreement for the Biomek NGeniuS System
INDIANAPOLIS – (October 31, 2022) – More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, for their next generation sequencing (NGS) needs with the Biomek NGeniuS System. The company continues building a robust demonstrated application library as it announces an application development agreement with
Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference
NATICK, Mass. – August 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, today announced that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will
Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference Read More »
Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass. – August 22, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall
Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit
NATICK, Mass. – August 5, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, today announced that Randy Pritchard, Chief Executive Officer, will participate in the “Liquid Biopsy in
Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
– PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass. – July 19, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision
Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer
NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Bioscience’s
Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology
Study entitled “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting NATICK, Mass. – May 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing
Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants
– Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy – These data, plus three additional studies, presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting NATICK, Mass. – April 11, 2022 – (BUSINESS WIRE) – Pillar
Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel
NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel. Both executives join Pillar Biosciences with more than 20 years of experience in their